4-甲基-5-氨基吲哚 | 196205-06-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 4-甲基-5-氨基吲哚
• 中文别名: 5-氨基-4-甲基吲哚
• 英文名称: 5-amino-4-methylindole
• 英文别名: 4-methyl-5-aminoindole；4-methyl-1H-indol-5-amine
• CAS: 196205-06-8
• 化学式: C₉H₁₀N₂
• mdl: MFCD08704548
• 分子量: 146.192
• InChiKey: LLUMZCODEQVYRF-UHFFFAOYSA-N

物化性质

• 沸点：
  352.6±22.0 °C(Predicted)
• 密度：
  1.213±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  41.8
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  4-甲基-5-氨基吲哚 、 4-氯-2-碘噻吩并[2,3-b]吡啶-5-甲腈 以 乙醇 为溶剂， 生成 2-Iodo-4-[(4-methyl-1H-indol-5-yl)amino]thieno[2,3-b]pyridine-5-carbonitrile
  参考文献：
  名称：

  Synthesis and PKCθ inhibitory activity of a series of 4-(indol-5-ylamino)thieno[2,3-b]pyridine-5-carbonitriles

  摘要：

  The thieno[2,3-b]pyridine-5-carbonitrile with a 5-indolylamine at C-4 and a phenyl group at C-2 had a moderate activity against PKC theta. Optimization of the groups at C-4 and C-2 led to analog 29, which has an IC50 value of 7.5 nM for the inhibition of PKC theta. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.03.077
• 作为产物：
  描述：

  4-甲基-5-硝基-1H-吲哚 在 palladium-carbon 作用下， 以 甲醇 为溶剂， 以95%的产率得到4-甲基-5-氨基吲哚
  参考文献：
  名称：

  5- and 6-(2-imidazolin-2-ylamino) and

  摘要：

  这项发明涉及选择性作用于克隆人类α2受体的吲哚和苯并噻唑化合物。该发明还涉及这些化合物在任何需要使用α2激动剂的适应症中的用途。具体包括用作镇痛剂、镇静剂和麻醉剂。此外，该发明包括使用这些化合物降低眼内压、治疗老花眼、偏头痛、高血压、酒精戒断、药物成瘾、类风湿性关节炎、缺血性疼痛、痉挛、腹泻、鼻塞、尿失禁，以及用作认知增强剂和眼部血管收缩剂。该发明还提供一种包含上述定义化合物的治疗有效量和药用可接受载体的药物组合物。

  公开号：

  US05677321A1

文献信息

• [EN] BENZOTHIADIAZINE COMPOUNDS<br/>[FR] COMPOSÉS BENZOTHIADIAZINE
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2017098421A1

  公开（公告）日：2017-06-15

  The invention is directed to substituted benzothiadiazine derivatives. Specifically, the invention is directed to compounds according to Formula (I):wherein R, R1, R2, R3, R4 and R5 are as defined herein. The compounds of the invention are inhibitors of CD73 and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with CD73 inhibition, such as AIDS, autoimmune diseases, infections, atherosclerosis, and ischemia-reperfusion injury. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CD73 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及取代苯并噻二嗪衍生物。具体而言，本发明涉及式(I)化合物：其中R、R1、R2、R3、R4和R5定义如下。本发明的化合物是CD73的抑制剂，可用于治疗癌症、前癌综合症和与CD73抑制相关的疾病，如艾滋病、自身免疫病、感染、动脉粥样硬化和缺血-再灌注损伤。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明更进一步的涉及使用本发明化合物或包含本发明化合物的药物组合物抑制CD73活性和治疗相关疾病的方法。
• Substituted 3-cyanopyridines as protein kinase inhibitors
  申请人：Cole Cecil Derek

  公开号：US20070287708A1

  公开（公告）日：2007-12-13

  The present teachings provide compounds of formula I and their pharmaceutically acceptable salts, hydrates, and esters, wherein R 1 , R 2 , and X are as defined herein. The present teachings also provide methods of making the compounds of formula I, and methods of treating autoimmune and inflammatory diseases by administering a therapeutically effective amount of a compound or compounds of formula I to a mammal including a human.

  本发明的教导提供了公式I的化合物及其药用可接受的盐、水合物和酯，其中R1、R2和X如本文所述定义。本发明的教导还提供了制造公式I化合物的方法，以及通过向哺乳动物包括人类施用治疗有效量的公式I化合物或化合物来治疗自身免疫性和炎症性疾病的方法。
• Thieno [2,3-B] pyridine-5-carbonitriles as protein kinase inhibitors
  申请人：Boschelli H. Diane

  公开号：US20070082880A1

  公开（公告）日：2007-04-12

  Disclosed are compounds of Formula I: wherein R 1 , R 2 , R 3 , R 4 , and X, are defined hereinbefore in the specification, which can be useful in the treatment of autoimmune and inflammatory diseases, and processes for producing said compounds.

  公开了以下公式I的化合物：其中R1、R2、R3、R4和X在规范中已定义，这些化合物可以用于治疗自身免疫和炎症性疾病，并且公开了生产这些化合物的过程。
• [EN] INDOLE-SUBSTITUTED 3-CYANOPYRIDINES AS KINASE INHIBITORS<br/>[FR] 3-CYANOPYRIDINES INDOLE-SUBSTITUÉES EN TANT QU'INHIBITEURS DE KINASE
  申请人：WYETH CORP

  公开号：WO2009076571A1

  公开（公告）日：2009-06-18

  Disclosed are compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein X is -O-, -N(R3)-, -S-, -S(O)- or -S(O)2-; R2 is a C1-4 alkyl group or -CF3; and R1, R3, R4 and p are as defined herein; wherein the compounds are useful as kinase inhibitors. Also disclosed are pharmaceutical compositions containing, and intermediate compounds and methods for making the compounds of formula (I) and their pharmaceutically acceptable salts; and methods of using the foregoing to treat inflammatory and autoimmune diseases such as asthma, colitis, multiple sclerosis, psoriasis, arthritis, rheumatoid arthritis, inflammatory bowel disease, and joint inflammation.

  揭示了具有以下结构的化合物（I）及其药学上可接受的盐，其中X为-O-、-N(R3)-、-S-、-S(O)-或-S(O)2-；R2为C1-4烷基或-CF3；而R1、R3、R4和p如本文所定义；这些化合物可用作激酶抑制剂。还揭示了含有这些化合物的药物组合物，以及制备这些化合物及其药学上可接受的盐的中间体化合物和方法；以及利用上述化合物来治疗炎症和自身免疫性疾病，如哮喘、结肠炎、多发性硬化症、牛皮癣、关节炎、类风湿关节炎、炎症性肠病和关节炎的方法。
• Process for the preparation of 4-hydroxythieno[2,3-b]pyridine-5-carbonitriles
  申请人：Boschelli Harris Diane

  公开号：US20080076926A1

  公开（公告）日：2008-03-27

  A process for the preparation of 4-hydroxythieno[2,3-b]pyridine-5-carbonitriles, which can be useful for the preparation of protein kinase inhibitors, is provided.

  提供一种制备4-羟基噻吩[2,3-b]吡啶-5-碳腈的方法，该方法可用于制备蛋白激酶抑制剂。